NTLA Intellia Therapeutics, Inc.

NTLA Intellia Therapeutics, Inc.

Healthcare · Biotechnology

Desk view

Passedbiotech.json: price $12.09 below $18.50 trigger, consistent w/ no ran_note; trend down matches row. Clinical-stage biotech, no product revenue, own trend is down — a pre-rev lottery. (2026-08-13)
Basis Open desk call ·Logged decision
Updated

Market read

Scan convergence 2 scans as of 2026-08-17 1 bear 1 neutral converging

POC $13.45 · VWAP $13.67 · -11.6% vs 12m avg buyer

collapse vol: compressedgaps: overnight-shiftchurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

NTLA Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist NTLA belongs to, members best 30-day change first — NTLA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@biotech
@ibb
@biotech-scan
@insider-universe
View watchlist →
U+56.8% -1.7%1d +5.5%7d MDB+40.5% -4.7%1d +5.3%7d FSLY+40.1% -3.0%1d +4.6%7d ESTC+35.5% -3.7%1d +9.4%7d PLTR+30.3% -0.9%1d -1.5%7d MRVL+24.2% +5.5%1d +12.4%7d ZS+23.0% +0.5%1d +4.5%7d ABNB+22.8% -2.6%1d -2.9%7d SNOW+22.8% +0.4%1d -1.4%7d MSFT+22.0% -3.0%1d -5.0%7d SHOP+20.3% -3.7%1d -4.2%7d ZM+15.8% -0.4%1d -1.5%7d ASAN+14.8% -3.4%1d -4.2%7d NOW+14.0% -5.1%1d -7.6%7d DOCN+13.8% +4.1%1d +4.3%7d CRSP+13.6% +1.4%1d +1.6%7d ISRG+13.0% -1.1%1d -0.8%7d CRM+11.8% -2.7%1d -3.3%7d NVDA+10.9% -0.1%1d +3.4%7d NET+10.6% -2.8%1d -1.1%7d TWLO+10.6% -4.0%1d -8.8%7d NFLX+10.3% -2.7%1d -0.3%7d CEG+10.2% -1.5%1d +2.9%7d TMO+10.0% -0.5%1d -2.3%7d INTC+8.9% +1.0%1d +6.1%7d TSM+8.2% +1.1%1d +3.0%7d BE+8.0% +1.0%1d +10.2%7d ASML+7.9% +2.1%1d +8.6%7d UIE+6.9% +1.9%1d +2.1%7d NTLA+6.2% +1.5%1d +0.6%7d VRTX+6.2% +1.9%1d -1.6%7d SOFI+6.0% +0.1%1d +1.2%7d AVGO+5.8% -0.1%1d -7.1%7d AMZN+5.7% -0.5%1d -6.0%7d CRWD+5.3% -1.4%1d -5.0%7d PANW+4.8% -2.2%1d -2.4%7d MRNA+4.3% +1.8%1d +7.7%7d IBKR+4.2% +2.5%1d +4.1%7d UBER+3.5% -1.3%1d -3.9%7d FSLR+2.8% -3.4%1d -8.9%7d AKAM+2.3% -1.6%1d +4.6%7d AMD+2.1% -1.6%1d +7.8%7d ARM+1.6% -2.9%1d +1.4%7d LLY+0.3% +0.3%1d -3.8%7d BNTX+0.1% -1.6%1d -1.3%7d PINS-0.6% -4.1%1d -5.3%7d GOOGL-0.8% -0.6%1d -3.8%7d AFRM-2.0% -4.9%1d -1.4%7d FTNT-3.6% -2.6%1d -5.1%7d COIN-4.2% +1.4%1d +1.3%7d DDOG-4.4% -3.2%1d -5.2%7d EOSE-5.1% -2.5%1d -3.0%7d QCOM-5.6% -2.2%1d 0.0%7d ENPH-7.0% -4.5%1d -5.5%7d AAPL-8.4% -0.1%1d -0.8%7d TSLA-10.9% -0.9%1d +2.5%7d META-11.9% -3.5%1d -4.4%7d HIMS-12.9% +1.6%1d -9.9%7d RBLX-26.6% -0.8%1d +2.3%7d

Desk commentary

Authored analysis and challenge notes tied to NTLA.

1

Next earnings NTLA reports in 79 days Nov 5

Last report May 7

Reported the quarter ending 2026-03-31: revenue $15M, diluted EPS $-0.81, net income $-96M (SEC filing). Across the print the stock moved +1.7% (close before → first close after).

full note →

Against street estimates

How NTLA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 10 quarters · newest report Aug 6 · projection Aug 17

Result
Aug 6 -0.78-0.80-1.9%In line
May 11 -0.90-0.81+9.8%Beat
Feb 26 -0.96-0.83+13.7%Beat
Nov 6 '25 -0.98-0.92+6.6%Beat
Aug 7 '25 -1.01-0.98+2.5%Beat
May 8 '25 -1.27-1.10+13.5%Beat
Feb 27 '25 -1.32-1.27+3.5%Beat
Nov 7 '24 -1.37-1.34+2.1%Beat

News (last pull)

Headlines about NTLA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 19 days ago · Jul 30

Types
Aug 6 Catalyst NTLA earnings
May 7 Catalyst NTLA earnings